Welcome to our dedicated page for Telomir Pharmaceuticals news (Ticker: TELO), a resource for investors and traders seeking the latest updates and insights on Telomir Pharmaceuticals stock.
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) is a preclinical-stage biotechnology company whose news flow centers on Telomir-1, its lead small-molecule candidate targeting epigenetic and metabolic drivers of cancer, aging, and age-related disease. Company press releases and corresponding 8‑K filings provide detailed updates on preclinical data, regulatory progress, and corporate developments related to this program.
Investors following TELO news will find frequent reports on oncology studies, including results in triple-negative breast cancer, prostate cancer, pancreatic cancer, and leukemia models. Recent announcements describe Telomir-1’s effects on tumor growth and metastatic spread in TNBC xenografts, reductions in PSA levels and tumor volume in prostate cancer systems, and dose-dependent cytotoxicity in aggressive leukemia cells. Other updates highlight Telomir-1’s impact on DNA methylation of tumor-suppressor genes and its inhibition of iron-dependent histone demethylases.
Another key category of Telomir news involves IND-enabling and safety milestones. The company has reported completion of GLP toxicology and safety pharmacology studies in rat and dog models, noting favorable tolerability and consistent systemic exposure after oral dosing. These items are often disclosed both via press release and in Item 8.01 sections of Form 8‑K, giving additional regulatory context.
Corporate and strategic developments also appear in TELO’s news stream. Examples include the binding Letter of Intent to acquire TELI Pharmaceuticals, Inc. to consolidate worldwide rights to Telomir-1, and Nasdaq communications regarding listing rule compliance for annual shareholder meetings. Together, these updates provide insight into Telomir’s scientific progress, regulatory planning, and corporate positioning as it advances Telomir-1 toward potential clinical evaluation.
Telomir Pharmaceuticals (TELO) reported new preclinical research showing its lead candidate Telomir‑Zn inhibited cell growth in human and canine osteosarcoma models.
The Ohio State University College of Veterinary Medicine evaluated Telomir‑Zn in three osteosarcoma cell lines (HOS human, D17 and Abrams canine) and observed dose-dependent anti-tumor activity with growth inhibition at similar low drug concentrations. These in-vitro findings support further translational investigation in naturally occurring canine osteosarcoma while Telomir’s triple‑negative breast cancer (TNBC) program advances toward site initiation and Phase 1/2 enrollment under an FDA‑cleared IND.
Telomir is assessing a dual development pathway: TNBC in humans as the lead indication and potential in vivo canine osteosarcoma studies that could support both veterinary and human oncology applications.
Telomir (NASDAQ:TELO) reported peer-reviewed preclinical data showing its small molecule Telomir-Zn suppressed tumor growth in triple-negative breast cancer (TNBC) and prostate cancer models by modulating intracellular iron and copper to inhibit JmjC histone demethylases (KDM2, KDM5, KDM6).
Iron-rescue experiments confirmed the anti-cancer effect depended on iron depletion, with Telomir-Zn selectively killing iron-dependent TNBC cells while sparing normal cells at over 50-fold higher concentrations. In xenograft models, Telomir-Zn reduced primary TNBC tumor size, showed anti-metastatic activity in HCC1806, enhanced paclitaxel effects in BT-549, but did not affect MDA-MB-231 tumors. These findings support Telomir’s planned Phase 1/2 TNBC trial under an active IND.
Telomir Pharmaceuticals (NASDAQ:TELO) reported a peer-reviewed publication in Biomedicine & Pharmacotherapy showing Telomir‑Zn restored insulin sensitivity and improved glucose homeostasis in a diet-induced zebrafish Type 2 diabetes model.
After 14 days, HOMA-IR fell from about 10–12 to ~3, with dose-dependent effects, supporting Telomir‑Zn's metal‑homeostasis mechanism and its FDA‑cleared Phase 1/2 TNBC program.
Telomir Pharmaceuticals (NASDAQ:TELO) announced a peer-reviewed preclinical study of Telomir-Zn in a Wilson's disease zebrafish model, published in Advances in Redox Research. Telomir-Zn showed dose-dependent survival improvement, reduced hepatic copper, better liver biomarkers, improved locomotor function, less tissue degeneration, and multiple oxidative-stress pathway benefits.
The data represent the first peer-reviewed Wilson's disease publication for Telomir-Zn and, according to Telomir, support its broader mechanistic approach, including its lead Triple-Negative Breast Cancer program cleared by the FDA for IND in April 2026.
Telomir Pharmaceuticals (NASDAQ:TELO) announced FDA clearance of its IND for Telomir-Zn to treat advanced or metastatic triple-negative breast cancer (TNBC). The clearance enables a first-in-human, multicenter Phase 1/2 study (TELO-001) planned for 1H 2026 with ~76 patients to assess safety, PK/PD, and preliminary antitumor activity.
The study includes dose escalation and expansion, integrated biomarker analyses of epigenetic modulation and telomere biology, and aims to identify potential predictive biomarkers.
Telomir Pharmaceuticals (NASDAQ:TELO) completed its acquisition of TELI Pharmaceuticals on April 24, 2026, consolidating global rights to Telomir-1 (Telomir-Zn) under one company and making TELI a wholly owned subsidiary.
The deal included $1.0 million funded at closing and up to an additional $4.0 million in optional, milestone-based contributions tied to IND acceptance and Phase 1/2 initiation. Telomir has submitted an IND for Telomir-Zn aimed at advanced/metastatic triple-negative breast cancer and plans a Phase 1/2 oral monotherapy trial if cleared.
Telomir Pharmaceuticals (NASDAQ:TELO) submitted an IND to the FDA on March 31, 2026 for Telomir-1 (Telomir-Zn), a first-in-class metal-modulating epigenetic small molecule for advanced and metastatic triple-negative breast cancer (TNBC). The IND includes IND-enabling pharmacology, GLP toxicology, and manufacturing data, and the company plans a Phase 1/2 oral monotherapy trial pending clearance.
Preclinical results showed tumor growth and metastasis reduction, enhanced activity with chemotherapy, favorable GLP safety with no dose-limiting toxicities, and planned biomarker strategies to guide development.
Telomir Pharmaceuticals (NASDAQ:TELO) reported in vitro data showing Telomir-Zn induces iron-dependent tumor cell mortality across multiple triple-negative breast cancer (TNBC) models. MDA-MB-468 showed near-complete cell death at 72 hours; two other models had significant partial mortality. The company plans an IND submission in Q1 2026 and is completing additional TNBC and mammalian xenograft studies.
Telomir Pharmaceuticals (NASDAQ:TELO) reported preclinical cellular data showing its investigational compound Telomir-Zn rapidly increases intracellular zinc while reducing labile ferrous iron in cultured human cells. Effects occurred within 30 minutes and were sustained for two hours at low-micromolar doses without cytotoxicity. The company links this coordinated metal modulation to potential impacts on oxidative stress, mitochondrial function, DNA methylation, telomere stability, and genomic integrity, and plans an IND submission in Q1 2026 while preparing scientific presentations and manuscript submissions.
Telomir Pharmaceuticals (NASDAQ:TELO) reported preclinical efficacy for Telomir-1 in zebrafish TNBC xenograft models on January 5, 2026. Telomir-1 produced statistically significant reductions in primary tumor growth and metastatic dissemination in aggressive TNBC models, including an HCC1806 model with limited paclitaxel responsiveness.
Telomir-1 matched paclitaxel activity in a BT-549 model and enhanced tumor inhibition when combined with paclitaxel. No activity was seen in an MDA-MB-231 resistant model. The company is advancing IND-enabling activities and refining patient-selection strategies.